BioMarin reports Q4 revenue $747M (+16%), full-year GAAP EPS $2.21, guides 2025 rev growth ~10%

BIOMARIN PHARMACEUTICAL INC

2024-FY EPS reported $2.21 revenue$2,853,915,000

Q4 total revenue $747M (+16% YoY); full-year $2.854B (+18%). GAAP diluted EPS $0.64 (Q4) and $2.21 (FY), up 154% YoY.
Non-GAAP diluted EPS $0.92 (Q4) and $3.52 (FY), up 69% YoY. Non-GAAP operating margin 28.6% for FY, up 9.2 ppts.
VOXZOGO revenue $208M in Q4 (+42%), $735M full-year (+56%); on track for >25% CAGR 2023-2027.
FY 2025 guidance: total revenue growth ~10% at midpoint; non-GAAP diluted EPS growth ~22%; targeting $4B revenue by 2027.
Pipeline: BMN 333 (CNP) first-in-human dosed, BMN 351 DMD data H2 2025; PALYNZIQ adolescent study data mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.